Raymond James Starts Maze Therapeutics (MAZE) at Outperform

Raymond James analyst Martin Auster initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Outperform rating and a price target of $48.00.

The analyst comments "We initiate coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target. The Maze Compass platform leverages genetic insights to discover novel therapies for genetically validated targets. MAZE’s lead wholly-owned assets target high unmet need chronic kidney disease (CKD) populations: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1- mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor entering Phase 2 in phenylketonuria (PKU) and CKD. Both assets have best-in-class potential in attractive commercial indications and encouraging early mechanistic de-risking, in our view. While shares have roughly doubled from the January 2025 IPO, we believe MAZE continues to offer a very compelling risk/ reward skew into key Phase 2 readouts for MZE829 and MZE782 beginning in 2026."

For an analyst ratings summary and ratings history on Maze Therapeutics click here. For more ratings news on Maze Therapeutics click here.

Shares of Maze Therapeutics closed at $32.56 yesterday.

You May Also Be Interested In

• Maze Therapeutics (MAZE) Misses Q2 EPS by 19c
• NeuroPace (NPCE) Tops Q2 EPS by 3c
• Fermi strikes 2.6 GW power deal with Hillcore for Texas AI campus